Lorcainide (BioDeep_00000036551)
human metabolite Chemicals and Drugs
代谢物信息卡片
化学式: C22H27ClN2O (370.1812)
中文名称: 洛开酰胺
谱图信息:
最多检出来源 Homo sapiens(endogenous) 43.21%
分子结构信息
SMILES: CC(C)N1CCC(CC1)N(C(=O)CC1=CC=CC=C1)C1=CC=C(Cl)C=C1
InChI: InChI=1S/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3
描述信息
Cardiac dysrhythmia is a heart rate disorder that manifests as an altered cardiac rhythm. It results from either abnormal pacemaker activity or a disturbance in impulse propagation, or both. Arrhythmias can be caused by various conditions including ischemia, hypoxia, pH disruptions, B adrenergic activation, drug interactions or the presence of diseased tissue. These events can trigger the development of ectopic pacemaker in the heart, which emit abnormal impulses at random times during the cardiac cycle. An arrhythmia can present itself as either bradycardia or tachycardia. Untreated arrhythmias may progress to atrial fibrillation or ventricular fibrillation. Treatment is aimed at normalizing cardiac rhythm by altering ion flow across the membrane. Antiarrhythmic agents can reduce arrhythmia related symptoms such as palpitations or syncope; however, they often have a narrow therapeutic index and can also be proarrhythmic. Lorcainide (Lorcainide hydrochloride) is a Class 1c antiarrhythmic agent that is used to help restore normal heart rhythm and conduction in patients with premature ventricular contractions, ventricular tachycardiac and Wolff-Parkinson-White syndrome. Lorcainide was developed by Janssen Pharmaceutica (Belgium) in 1968 under the commercial name Remivox and is designated by code numbers R-15889 or Ro 13-1042/001. It has a half-life of 8.9 +- 2.3 hrs which may be prolonged to 66 hrs in people with cardiac disease. Wolff-Parkinson-White syndrome (WPW) is a pre-excitation syndrome in which individuals are predisposed to supraventricular tachyarrhythmias (rapid and irregular heart beats). People with this condition have an extra or accessory atrioventricular conduction pathway that causes re-entry tachycardia. WPW is characterized by a short PR interval (<0.12 second) and a prolonged, slurred QRS complex (>0.12 seconds).
C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BC - Antiarrhythmics, class ic
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
同义名列表
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:135568
- PubChem: 42884
- HMDB: HMDB0041918
- DrugBank: DB13653
- ChEMBL: CHEMBL87543
- Wikipedia: Lorcainide
- chemspider: 39116
- CAS: 59729-31-6
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Hongliang Li, Wenwen Zhuang, Mi Seon Seo, Jin Ryeol An, Yongqi Yang, Yiwen Zha, Jingyan Liang, Zheng-Xin Xu, Won Sun Park. Inhibition of voltage-dependent K+ channels in rabbit coronary arterial smooth muscle cells by the class Ic antiarrhythmic agent lorcainide.
European journal of pharmacology.
2021 Aug; 904(?):174158. doi:
10.1016/j.ejphar.2021.174158. [PMID: 33971179] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - B Paw, L Przyborowski. Identification of flecainide and lorcainide in blood by means of TLC.
Acta poloniae pharmaceutica.
1995 Jan; 52(1):5-7. doi:
NULL. [PMID: 8960234] - X Luo, F D Zeng. [HPLC method for determination of lorcainide hydrochloride in human serum].
Yao xue xue bao = Acta pharmaceutica Sinica.
1995; 30(8):605-9. doi:
NULL. [PMID: 8571780] - E G Giardina, K Raby, A L Saroff, M Louie-Chu. Antiarrhythmic effect of lorcainide in patients taking digoxin.
Journal of clinical pharmacology.
1987 May; 27(5):378-83. doi:
10.1002/j.1552-4604.1987.tb03034.x. [PMID: 3693581] - P Somani, T D Fraker, P N Temesy-Armos. Pharmacokinetic implications of lorcainide therapy in patients with normal and depressed cardiac function.
Journal of clinical pharmacology.
1987 Feb; 27(2):122-32. doi:
10.1002/j.1552-4604.1987.tb02172.x. [PMID: 3680563] - E Carmeliet. Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide.
European journal of pharmacology.
1987 Jan; 133(1):29-36. doi:
10.1016/0014-2999(87)90202-0. [PMID: 3556390] - V Plänitz, J Grönniger, E Jähnchen. Prehepatic and hepatic first-pass metabolism of lorcainide in rats.
Arzneimittel-Forschung.
1985; 35(6):923-6. doi:
NULL. [PMID: 4026917] - R Stroobandt, H Kesteloot. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
Acta cardiologica.
1985; 40(6):637-48. doi:
NULL. [PMID: 3879420] - R H Mead, D L Keefe, R E Kates, R A Winkle. Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.
The American journal of cardiology.
1985 Jan; 55(1):72-8. doi:
10.1016/0002-9149(85)90302-9. [PMID: 2578245] - C F Gelijkens, A Van Peer, H Lenoir, A Knaeps, R Woestenborghs, J Heykants. The use and limitations of deuterated lorcainide in metabolism and pharmacokinetic studies.
Biomedical mass spectrometry.
1985 Jan; 12(1):38-42. doi:
10.1002/bms.1200120108. [PMID: 3157409] - P Somani, P N Temesy-Armos, R F Leighton, L S Goodenday, T D Fraker. Hyponatremia in patients treated with lorcainide, a new antiarrhythmic drug.
American heart journal.
1984 Dec; 108(6):1443-8. doi:
10.1016/0002-8703(84)90690-2. [PMID: 6507240] - G P Sanna. New drugs in the management of ventricular arrhythmias.
Giornale italiano di cardiologia.
1984 Oct; 14(10):788-97. doi:
. [PMID: 6083894] - A M Gillis, R E Kates. Clinical pharmacokinetics of the newer antiarrhythmic agents.
Clinical pharmacokinetics.
1984 Sep; 9(5):375-403. doi:
10.2165/00003088-198409050-00001. [PMID: 6437721] - D G McDevitt. The clinical pharmacology of lidocaine congeners--review of encainide, flecainide, lorcainide and tocainide.
European heart journal.
1984 Sep; 5 Suppl B(?):63-6. doi:
10.1093/eurheartj/5.suppl_b.63. [PMID: 6437818] - D L Keefe, R E Kates, R A Winkle. Comparative electrophysiology of lorcainide and norlorcainide in the dog.
Journal of cardiovascular pharmacology.
1984 Sep; 6(5):808-15. doi:
10.1097/00005344-198409000-00011. [PMID: 6209484] - P Somani, V Simon, R K Gupta, P King, R S Shapiro, H Stockard. Lorcainide kinetics and protein binding in patients with end-stage renal disease.
International journal of clinical pharmacology, therapy, and toxicology.
1984 Mar; 22(3):121-5. doi:
NULL. [PMID: 6715079] - R A Winkle, D L Keefe, I Rodriguez, R E Kates. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
The American journal of cardiology.
1984 Feb; 53(4):544-51. doi:
10.1016/0002-9149(84)90028-6. [PMID: 6198895] - R E Kates. Metabolites of cardiac antiarrhythmic drugs: their clinical role.
Annals of the New York Academy of Sciences.
1984; 432(?):75-89. doi:
10.1111/j.1749-6632.1984.tb14510.x. [PMID: 6441496] - H Leinonen, J Heikkilä, S Sundberg, A Gordin. Lorcainide in the prophylaxis of ventricular arrhythmias in acute myocardial infarction.
Annals of clinical research.
1984; 16(1):18-22. doi:
NULL. [PMID: 6378045] - W Meuldermans, R Hurkmans, E Swysen, J Hendrickx, J Thijssen, W Lauwers, J Heykants. Excretion and metabolism of lorcainide in rats, dogs and man.
European journal of drug metabolism and pharmacokinetics.
1983 Oct; 8(4):335-49. doi:
10.1007/bf03188766. [PMID: 6673971] - W F Lauwers, W E Meuldermans, J O Bracke. Mass spectral investigation of the metabolites of lorcainide in man.
European journal of drug metabolism and pharmacokinetics.
1983 Oct; 8(4):351-62. doi:
10.1007/bf03188767. [PMID: 6673972] - D S Echt, L B Mitchell, R E Kates, R A Winkle. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
Circulation.
1983 Aug; 68(2):392-9. doi:
10.1161/01.cir.68.2.392. [PMID: 6861314] - F Follath, U Ganzinger, E Schuetz. Reliability of antiarrhythmic drug plasma concentration monitoring.
Clinical pharmacokinetics.
1983 Jan; 8(1):63-82. doi:
10.2165/00003088-198308010-00004. [PMID: 6404580] - R E Kates, D L Keefe, R A Winkle. Lorcainide disposition kinetics in arrhythmia patients.
Clinical pharmacology and therapeutics.
1983 Jan; 33(1):28-34. doi:
10.1038/clpt.1983.4. [PMID: 6848296] - D L Keefe, F Peters, R A Winkle. Randomized double-blind placebo controlled crossover trial documenting oral lorcainide efficacy in suppression of symptomatic ventricular tachyarrhythmias.
American heart journal.
1982 Apr; 103(4 Pt 1):511-8. doi:
10.1016/0002-8703(82)90338-6. [PMID: 7039282] - T Meinertz, W Kasper, E Stengel, B Waldecker, H Löllgen, E Jähnchen, H Bechtold, J Just. Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias.
Zeitschrift fur Kardiologie.
1982 Jan; 71(1):35-8. doi:
NULL. [PMID: 7039160] - P Somani. Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders.
The American journal of cardiology.
1981 Jul; 48(1):157-63. doi:
10.1016/0002-9149(81)90585-3. [PMID: 7246437] - Y G Yee, R E Kates. High-performance liquid chromatographic analysis of lorcainide and its active metabolite, norlorcainide, in human plasma.
Journal of chromatography.
1981 May; 223(2):454-9. doi:
10.1016/s0378-4347(00)80122-x. [PMID: 7251802] - W K Amery, J J Heykants, R Xhonneux, G Towse, P Oettel, D A Gough, P A Janssen. Lorcainide (R 15 889), a first review.
Acta cardiologica.
1981; 36(3):207-34. doi:
NULL. [PMID: 7020313] - T Meinertz, W Kasper, F Kersting, H Bechtold, H Just, E Jähnchen. Antiarrhythmic effect of lorcainide during chronic treatment.
Arzneimittel-Forschung.
1980; 30(9):1593-5. doi:
NULL. [PMID: 7193031] - U Klotz, E Golbs. The pharmacokinetics and tissue distribution of the new antiarrhythmic agent lorcainide (R 15889) in rats.
Arzneimittel-Forschung.
1980; 30(4):619-21. doi:
NULL. [PMID: 7190402] - R Woestenborghs, M Michiels, J Heykants. Simultaneous gas chromatographic determination of lorcainide hydrochloride and three of its principal metabolites in biological samples.
Journal of chromatography.
1979 Oct; 164(2):169-76. doi:
10.1016/s0378-4347(00)81185-8. [PMID: 541407] - U Klotz, C Fischer, P Müller-Seydlitz, J Schulz, W A Müller. Alterations in the disposition of differently cleared drugs in patients with cirrhosis.
Clinical pharmacology and therapeutics.
1979 Aug; 26(2):221-7. doi:
10.1002/cpt1979262221. [PMID: 455890] - T Meinertz, W Kasper, F Kersting, H Just, H Bechtold, E Jähnchen. Lorcainide. II. Plasma concentration-effect relationship.
Clinical pharmacology and therapeutics.
1979 Aug; 26(2):196-204. doi:
10.1002/cpt1979262196. [PMID: 455888] - U Klotz, P Müller-Seydlitz, P Heimburg. Disposition and antiarrhythmic effect of lorcainide.
International journal of clinical pharmacology and biopharmacy.
1979 Apr; 17(4):152-8. doi:
NULL. [PMID: 376458] - U Klotz, P Müller-Seydlitz, P Heimburg. Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent.
Clinical pharmacokinetics.
1978 Sep; 3(5):407-18. doi:
10.2165/00003088-197803050-00006. [PMID: 699462]
